KRAS and neoplasm: Furthermore, RASON inhibition enhances the therapeutic efficacy of AMG-510, a KRASG12C inhibitor, suggesting that RASON targeting could exert anti-tumor effects alone or synergize with existing KRAS-directed therapies to improve treatment outcomes.